Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Asm Nawshad Uddin Ahmed is active.

Publication


Featured researches published by Asm Nawshad Uddin Ahmed.


The Lancet | 2005

Effect of topical treatment with skin barrier-enhancing emollients on nosocomial infections in preterm infants in Bangladesh: a randomised controlled trial.

Gary L. Darmstadt; Samir K. Saha; Asm Nawshad Uddin Ahmed; Mak Azad Chowdhury; Paul A. Law; Saifuddin Ahmed; Muhammad Asif Alam; Robert E. Black; Mathuram Santosham

BACKGROUND Infections and complications of prematurity are main causes of neonatal mortality. Very low birthweight premature infants have compromised skin barrier function, and are at especially high risk for serious infections and mortality. Our aim was to ascertain whether topical application of emollients to enhance skin barrier function would prevent nosocomial infections in this population. METHODS We randomly assigned infants born before week 33 of gestation after admission to Dhaka Shishu Hospital, Bangladesh, to daily massage with sunflower seed oil (n=159) or Aquaphor (petrolatum, mineral oil, mineral wax, lanolin alcohol; n=157). We then compared incidence of nosocomial infections among infants in these two groups with an untreated control group (n=181) by an intention-to-treat analysis. FINDINGS 20 patients in the control group, and 22 in each of the treatment groups left the hospital early, but were included in the final analysis. Overall, infants treated with sunflower seed oil were 41% less likely to develop nosocomial infections than controls (adjusted incidence rate ratio [IRR] 0.59, 95% CI 0.37-0.96, p=0.032). Aquaphor did not significantly reduce the risk of infection (0.60, 0.35-1.03, p=0.065). No adverse events were seen. INTERPRETATION Our findings confirm that skin application of sunflower seed oil provides protection against nosocomial infections in preterm very low birthweight infants. The low cost, availability, simplicity, and effect of treatment make it an important intervention for very low birthweight infants admitted to hospital in developing countries.


Pediatric Infectious Disease Journal | 2006

Ciprofloxacin Treatment in Preterm Neonates in Bangladesh: Lack of Effects on Growth and Development

Asm Nawshad Uddin Ahmed; Naila Z. Khan; Samir K. Saha; Mak Azad Chowdhury; Humaira Muslima; Paul A. Law; Maksuda Islam; Mallika Bhattacharya; Gary L. Darmstadt

Background: Quinolone-induced arthropathic toxicity in weight-bearing joints observed in juvenile animals during preclinical testing has largely restricted the routine use of ciprofloxacin in the pediatric age group. As histopathologic, radiologic and magnetic resonance imaging monitoring evidence has gathered supporting the safety of fluoroquinolones in children, many pediatricians have started to prescribe quinolones to some patients on a compassionate basis. Objective: The objective of this study was to ascertain the safety of ciprofloxacin in preterm neonates <33 weeks gestational age treated at Dhaka Shishu (Children) Hospital in Bangladesh. Methods: Long-term follow up was done to monitor the growth and development of preterm infants who were administered intravenous ciprofloxacin in the neonatal period. Ciprofloxacin was used only as a life-saving therapy in cases of sepsis produced by bacterial agents resistant to other antibiotics. Another group of preterm neonates with septicemia who were not exposed to ciprofloxacin, but effectively treated with other antibiotics and followed up, were matched with cases for gender, gestational age and birth weight and included as a comparison group. Forty-eight patients in the ciprofloxacin group and 66 patients in the comparison group were followed up for a mean of 24.7 ± 18.5 months and 21.6 ± 18.8 months, respectively. Results: No osteoarticular problems or joint deformities were observed in the ciprofloxacin group during treatment or follow up. No differences in growth and development between the groups were found. Conclusions: Ciprofloxacin is a safe therapeutic option for newborns with sepsis produced by multiply resistant organisms.


Bulletin of The World Health Organization | 2010

Cost-effectiveness of skin-barrier-enhancing emollients among preterm infants in Bangladesh

Amnesty LeFevre; Samuel D. Shillcutt; Samir K. Saha; Asm Nawshad Uddin Ahmed; Saifuddin Ahmed; Mak Azad Chowdhury; Paul A. Law; Robert E. Black; Mathuram Santosham; Gary L. Darmstadt

OBJECTIVE To evaluate the cost-effectiveness of topical emollients, sunflower seed oil (SSO) and synthetic Aquaphor, versus no treatment, in preventing mortality among hospitalized preterm infants (< 33 weeks gestation) at a tertiary hospital in Bangladesh. METHODS Evidence from a randomized controlled efficacy trial was evaluated using standard Monte Carlo simulation. Programme costs were obtained from a retrospective review of activities. Patient costs were collected from patient records. Health outcomes were calculated as deaths averted and discounted years of life lost (YLLs) averted. Results were deemed cost-effective if they fell below a ceiling ratio based on the per capita gross national income of Bangladesh (United States dollars, US


Child Care Health and Development | 2008

Stress in mothers of preterm infants in Bangladesh: associations with family, child and maternal factors and children's neuro-development

Naila Zaman Khan; H. Muslima; Mallika Bhattacharya; R. Parvin; N. Begum; M. Jahan; D. Begum; S. Akhtar; Asm Nawshad Uddin Ahmed; Gary L. Darmstadt

470). FINDINGS Aquaphor and SSO were both highly cost-effective relative to control, reducing neonatal mortality by 26% and 32%, respectively. SSO cost US


Pediatric Infectious Disease Journal | 2014

Mechanism for Prevention of Infection in Preterm Neonates by Topical Emollients: A Randomized, Controlled Clinical Trial

Gary L. Darmstadt; Saifuddin Ahmed; Asm Nawshad Uddin Ahmed; Samir K. Saha

61 per death averted and US


Journal of Tropical Pediatrics | 2010

Nosocomial Sepsis Risk Score for Preterm Infants in Low-resource Settings

Rebecca E. Rosenberg; Asm Nawshad Uddin Ahmed; Samir K. Saha; Mak Azad Chowdhury; Saifuddin Ahmed; Paul A. Law; Robert E. Black; Mathuram Santosham; Gary L. Darmstadt

2.15 per YLL averted (I


PLOS ONE | 2016

Rotavirus surveillance at a who-coordinated invasive bacterial disease surveillance site in Bangladesh: A feasibility study to integrate two surveillance systems

Arif Mohammad Tanmoy; Asm Nawshad Uddin Ahmed; Rajesh Arumugam; Belal Hossain; Mahfuza Marzan; Shampa Saha; Shams El Arifeen; Abdullah H. Baqui; Robert E. Black; Gagandeep Kang; Samir K. Saha

6.39, international dollars, per YLL averted). Aquaphor cost US


Pediatric Infectious Disease Journal | 2009

Risk factors for sclerema neonatorum in preterm neonates in Bangladesh.

Amna Zeb; Rebecca E. Rosenberg; Asm Nawshad Uddin Ahmed; Samir K. Saha; Mak Azad Chowdhury; Saifuddin Ahmed; Gary L. Darmstadt

162 per death averted and US


Bulletin of The World Health Organization | 2009

Validation of community health workers’ assessment of neonatal illness in rural Bangladesh

Gary L. Darmstadt; Abdullah H. Baqui; Yoonjoung Choi; Sanwarul Bari; Syed Moshfiqur Rahman; Ishtiaq Mannan; Asm Nawshad Uddin Ahmed; Samir K. Saha; Radwanur Rahman; Stephanie Chang; Peter J. Winch; Robert E. Black; Mathuram Santosham; Shams El Arifeen

5.74 per YLL averted (I


BMC Public Health | 2016

Epidemiology and risk factors for pneumonia severity and mortality in Bangladeshi children <5 years of age before 10-valent pneumococcal conjugate vaccine introduction.

Shampa Saha; Hasan; Lindsay Kim; Jennifer L. Farrar; Belal Hossain; Maksuda Islam; Asm Nawshad Uddin Ahmed; M. Ruhul Amin; Mohammed Hanif; Manzoor Hussain; Shams El-Arifeen; Cynthia G. Whitney; Samir K. Saha

17.09 per YLL averted). Results were robust to sensitivity analysis. Aquaphor was cost-effective relative to SSO with 77% certainty: it cost an incremental US

Collaboration


Dive into the Asm Nawshad Uddin Ahmed's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul A. Law

Kennedy Krieger Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge